Anzeige
Mehr »
Login
Samstag, 20.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Breaking News: Voller Fokus auf NurExone Biologic!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
55 Leser
Artikel bewerten:
(0)

Perflow Medical Closes $12 Million in Financing to Treat Complex Neurovascular Disorders

And announces successful completion of over 50 commercial cases with the Stream' Dynamic Neuro-Thrombectomy Net

TEL AVIV, Israel, Feb. 15, 2018 /PRNewswire/ --Perflow Medical, an Israeli-based medical device company that develops innovative tools for neurovascular interventions, today announced that the company has closed $12 million in financing. The syndicate included existing investors, two new international investors, and an unnamed strategic investor. Following a recent launch in Europe, Perflow stated that over 50 mechanical thrombectomy procedures for the treatment of acute ischemic stroke have been successful completed with the Stream' Dynamic Neuro-Thrombectomy Net.

The new investment will support the commercialization of their first product, the Stream Net device, in Europe and select other countries and submission of the U.S. FDA 510(k) dossier. It will also support product development of two new products based on their patent-protected CEREBRAL NET' Technology platform for aneurysm neck bridging and flow diversion procedures.

Interventional Neurologist Marc Ribó, MD, PhD, at Hospital Vall d'Hebron in Barcelona, Spain and Interventional Neuroradiologist Anastasios Mpotsaris, MD, PhD, at Uniklinikum Aachen, Germany were the first physicians to use the novel device. "The Stream Net offers a new level of control that expands a physician's options to respond in real-time. My early experience with the system has been positive and I see it as a valuable addition to the market," commented Dr. Ribó. Sharing his experience Prof. Dr. med. Mpotsaris added, "The Stream's unique braided net design and device control help with clot retention during revascularization."

A next-generation thrombectomy device, the Stream Net is designed to address unmet clinical needs in the treatment of acute ischemic stroke, a leading cause of long-term disability that accounts for 5.5 million deaths annually worldwide. It offers the physician full device control of the braided net diameter, length, and radial force to create dynamic wall apposition and better clot retention during revascularization in tortious anatomy.

"This financing is a significant step and reflects the strong commitment our investors have to Perflow and the value of our proprietary CEREBRAL NET technology to empower physicians to improve outcomes," stated Danny Farin, CEO of Perflow Medical. "The clinical experience of the Stream Net device in Europe has been very encouraging and these funds will accelerate our ability to bring this life-saving technology to the market and continue to iterate novel neurovascular solutions using CEREBRAL NET technology."

About Perflow Medical

Perflow Medical, a privately owned Israeli-based medical device company, develops and manufactures innovative solutions to address complex neurovascular disorders. Perflow's patent-protected CEREBRAL NET' Technology platform, a dynamic braided net that enables adjustable neurovascular treatments, emphasizes physician expertise by combining real-time physician control, advanced device manipulation, full dynamic wall apposition, and excellent radiopacity to improve patient outcomes. Their first product, the Stream' Dynamic Neuro-Thrombectomy Net, is approved in Europe for the endovascular treatment of acute ischemic stroke. Learn more at www.perflow.com.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2018 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.